News

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...
Medical Marketing & Media1h
Rx Rundown: Sanofi, Processa Pharmaceuticals, Eli Lilly and more
AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.
Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...
Fierce Biotech4d
Eli Lilly's phase 1 amylin data impress analysts, pairing 11% weight loss with tolerable profile
Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...
Eli Lilly files lawsuits over other companies selling Zepbound and Mounjaro
INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
India's response to obesity drug Mounjaro 'positive', says Eli Lilly
Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug ...
Zacks Investment Research on MSN22h
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.